Planegg-Martinsried, Germany, 17 October 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma CTCL, today published its Q3 2024 report, presenting all material developments up to 30 September 2024, as well as the Company’s current outlook. The full report is available for […]
Swissmedic has granted Orphan Drug Status for resminostat for treatment of cutaneous T-cell lymphoma (CTCL) ODS benefits include reduced fees in Switzerland Planegg-Martinsried, Germany, 16 July 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage CTCL, received notification from the Swiss Agency for Therapeutic Products […]
Planegg-Martinsried, Germany, 20 June 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today publishes a summary of key highlights from its Annual General Meeting held earlier today in Martinsried, Germany. Read more…
Planegg-Martinsried, Germany, 18 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today published its Q1 2024 report, presenting all material developments up to 31 March 2024, as well as the Company’s current outlook. The full report is available for […]
Planegg-Martinsried, Germany, 22 March 2024 – 4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 2023, presenting all material reporting period developments and providing an outlook for 2024. The full report is available at 4SC’s website. Jason Loveridge, Ph.D., CEO of 4SC, commented: “2023 was a real breakout year for […]
